Latest News
- June 30, 2025Successful completion of 2 USFDA inspections with ZERO 483 in June 2025
- June 24, 2025Two USFDA inspections in ophthalmology, with ZERO 483
- June 17, 2025CBCC Brings the Community Together at BIO 2025!
- June 05, 2025Join CBCC at CPHI China 2025
- June 02, 2025Successfully completed a Phase 1a study for a US-based Innovator Biotech Company!
Webinar: Overview of the 505(b)(2) regulatory pathway for NDA
Keen on learning best practices, seize opportunities, and overcome challenges linked to IND submissions for products which fall under the 505(b)(2) regulatory pathway?
Access to the latest webinar on:
Overview of the 505(b)(2) regulatory pathway for NDA
Webinar Link: https://www.youtube.com/watch?v=dXW5UA9TFKA
Speakers:
Dr. Sandeep Singh (VP – Clinical Operations & Regulatory Affairs, CBCC Global Research)
Ankit Parikh (Senior Manager – Medical Writing & Regulatory Affairs, CBCC Global Research)
Moderator:
Manoj Bharathi (Director – Corporate Development, CBCC Global Research)
In this webinar, our expert will cover the unique components and customizations involved in 505(b)(2) IND submissions and study requirements.
You will learn:
Underlying common bottlenecks, regulatory requirements, as well as mitigating risk while charting out plans to stay ahead of timelines.